title: Topical application of dehydroxymethylepoxyquinomicin improves allergic inflammation via NF-kappaB inhibition.
authors.forename: Asuka
authors.initials: A
authors.lastname: Hamasaka
authors.forename: Naoya
authors.initials: N
authors.lastname: Yoshioka
authors.forename: Riichiro
authors.initials: R
authors.lastname: Abe
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kishino
authors.forename: Kazuo
authors.initials: K
authors.lastname: Umezawa
authors.forename: Michitaka
authors.initials: M
authors.lastname: Ozaki
authors.forename: Satoru
authors.initials: S
authors.lastname: Todo
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Shimizu
mesh_terms: D021581:Active Transport, Cell Nucleus / Q000187:drug effects; D000287:Administration, Topical; D000818:Animals; D001549:Benzamides / Q000494:pharmacology*; D002460:Cell Line; D003512:Cyclohexanones / Q000494:pharmacology*; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D004195:Disease Models, Animal; D006801:Humans; D051379:Mice; D016328:NF-kappa B / Q000037:antagonists & inhibitors* / Q000378:metabolism*
chemical_list: D001549:Benzamides; D003512:Cyclohexanones; D016328:NF-kappa B; C464444:dehydroxymethylepoxyquinomicin